103857-96-1

Basic information

• Product Name: 2-(2-METHOXY-PHENYL)-PYRROLIDINE
• Synonyms: 2-(2-METHOXY-PHENYL)-PYRROLIDINE;CHEMBRDG-BB 4002377;2-(2-methoxyphenyl)pyrrolidine(SALTDATA: 0.05H2O);Pyrrolidine,2-(2-Methoxyphenyl)-
• CAS NO: 103857-96-1
• Molecular Formula: C₁₁H₁₅NO
• Molecular Weight: 177.24
• Mol File: 103857-96-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 269℃
• Flash Point: 107℃
• Appearance: /
• Density: 1.024
• Vapor Pressure: 0.00726mmHg at 25°C
• Refractive Index: 1.524
• Storage Temp.: 2-8°C
• PKA: 10.06±0.10(Predicted)
• CAS DataBase Reference: 2-(2-METHOXY-PHENYL)-PYRROLIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-METHOXY-PHENYL)-PYRROLIDINE(103857-96-1)
• EPA Substance Registry System: 2-(2-METHOXY-PHENYL)-PYRROLIDINE(103857-96-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 103857-96-1(Hazardous Substances Data)

Usage

General Description

2-(2-Methoxy-phenyl)-pyrrolidine is a chemical compound that belongs to the class of phenylpyrrolidines. It is a nitrogen-containing heterocyclic compound that contains a five-membered ring structure with a methoxyphenyl group attached to one of the carbon atoms. 2-(2-METHOXY-PHENYL)-PYRROLIDINE may have potential pharmaceutical and therapeutic applications, as it can interact with various biological systems and exhibit activity as a neurotransmitter reuptake inhibitor. Additionally, it may also possess psychostimulant properties and has been the subject of research for its potential use in the treatment of certain medical conditions. However, further studies on its pharmacological properties and safety profile are needed to determine its suitability for pharmaceutical use.

InChI:InChI=1/C11H15NO/c1-13-11-7-3-2-5-9(11)10-6-4-8-12-10/h2-3,5,7,10,12H,4,6,8H2,1H3

Upstream product

• 67-56-1 methanol 
• 124-41-4 sodium methylate 
• 129540-24-5 2-(2-bromophenyl)pyrrolidine 
• 123-75-1 pyrrolidine 
• 31600-86-9 2-methoxyphenyllithium 
• 98464-65-4 5-(2-methoxyphenyl)-3,4-dihydro-2H-pyrrole 
• 914954-39-5 tert-butyl [4-(2-methoxyphenyl)-4-oxobutyl]carbamate 
• 16750-63-3 2-methoxyphenylmagnesium bromide 
• 113522-18-2 3-Dimethylamino-1-(2-methoxy-phenyl)-propan-1-one; hydrochloride 
• 113522-19-3 4-(2-methoxy-phenyl)-4-oxo-butyronitrile 

Relevant articles and documents

Bcl-2 INHIBITORS

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

Palladium-catalyzed ortho-olefination of 2-arylpyrrolidines: A tool for increasing structural complexity in nitrogen heterocycles

The dual role of the (2-pyridyl)sulfonyl unit as directing functionality and readily removable N-protecting group has enabled an efficient and practical transformation of 2-arylpyrrolidine derivatives into more complex tricyclic frameworks via palladium-catalyzed ortho-olefination with electron deficient alkenes and subsequent cyclization upon N-deprotection under mild conditions. The key cross coupling step in the presence of N-fluoro-2,4,6-trimethylpyridinium triflate ([F+]) as the terminal oxidant is both highly efficient and tolerant to a variety of steric and electronic changes at both coupling partners. By adequate choice of reductive conditions, the N-sulfonyl deprotection can be directed to the selective formation of benzo-fused pyrrolizidine or fused pyrrolidino-benzazapine frameworks.

SUBSTITUTED N-ARYLPYRROLIDINES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS

The present invention provides a compound of the formula: Formula I or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction comprising administering to a patient in need thereof an effective amount of a compound of Formula I.